Treatment of Hypoactive Delirium and Outcome Measures

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Haloperidol and Non-Pharmacologic Treatment are recognized treatments for delirium. This study will evaluate which is the best treatment for hypoactive delirium.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
• Treatments: Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria:

• Patients who fulfill criteria for delirium according to CAM and DOSS

• Patients in hospitalization who are not receiving treatment for delirium

• Patients without treatment with antipsychotics for any other reason

• Patients whose legally proxy accepts to participate

Exclusion Criteria:

• Patients who have received pharmacologic treatment for delirium

• Patients with a corrected QT interval prolongation

• Patients who receive antipsychotics for any other reason

• Patients in another age group

• Patients whose legally proxy does not accept to participate

• Patients with dementia

• Patients with Parkinson disease

• Patients with arrythmias

• Patients with language or hearing disorders that impede communication

• Patients hospitalized in the Intensive Care Unit

• Patients who are receiving benzodiazepines and anticholinergics

• Patients with dopamine agonists or antagonists

• Patients who develop a severe neurologic disease